Top 5 Drug Type | Count |
---|---|
Small molecule drug | 13 |
Proteolysis-targeting chimeras (PROTAC) | 3 |
Chemical drugs | 2 |
Recombinant polypeptide | 1 |
Synthetic peptide | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EphB4 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PI3Kδ inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date21 Feb 2025 |
Sponsor / Collaborator Tangdu Hospital [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Baichuan Jiangya Capsule | Hypertension More | Phase 2 |
(-)-Epicatechin gallate ( AHR x MMP2 x MMP9 x VEGF-A x caspase 3 ) | Atherosclerosis More | Preclinical |
SR-38832 ( TFs and related regulators ) | Colorectal Cancer More | Preclinical |
Os30 ( EGFR ) | Neoplasms More | Preclinical |
BD-7 ( HDACs ) | Neoplasms More | Preclinical |